5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats

Amin I. Kassis, Patrick Y. Wen, Annick D. Van Den Abbeele, Janina Baranowska-Kortylewicz, G. Mike Makrigiorgos, Kenneth R. Metz, Khalid Z. Matalka, Colin U. Cook, Shailendra K. Sahu, Peter Mc L. Black, S. James Adelstein

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Glial neoplasms of the human central nervous system have defied treatment, in part because of the limited selectivity of available cytotoxic agents. The thymidine analog 5-iodo-2'-deoxyuridine radiolabeled with the Auger electron emitter 125I (125IUdR) is highly toxic to dividing cells when it is deoxyribonucleic acid incorporated, but it is relatively innocuous when located outside the nucleus. Previous studies have shown that 125IUdR has significant antineoplastic potential against mammalian cells in vitro and direct administration of 125IUdR is effective therapy for ovarian ascites tumors in mice and neoplastic meningitis in rats. Studies using external gamma imaging and autoradiography have also shown that direct intratumoral administration of 123IUdR/125IUdR into intracerebral 9L gliosarcomas in rats results in selective uptake of the radionuclide into tumor cells. Based on these encouraging results, we have evaluated the therapeutic potential of 125IUdR in rats bearing intracerebral 9L gliosarcomas. Methods: Iodine- 125-IUdR was infused intracerebrally over a 2-day period into rats bearing 1- day-old 9L tumors and over a 6-day period into animals with 9-day-old 9L tumors; equimolar concentrations of 127IUdR were infused into control animals. Tumor growth was monitored by contrast-enhanced 1H MRI and animal survival was followed over time. Results: Intracerebral tumors (3-7 mm) were readily detected by MRI. Tumor-bearing rats treated with 127IUdR succumbed with 17-24 days, whereas tumor-bearing animals treated with 125IUdR survived significantly longer, and 10%-20% of the animals were cured of tumors. Conclusion: These data substantiate the antineoplastic potential of 5-[125I]iodo-2'-deoxyuridine and indicate that it may be a useful agent for the therapy of solid tumors that are accessible to direct radiopharmaceutical administration.

Original languageEnglish (US)
Pages (from-to)1148-1154
Number of pages7
JournalJournal of Nuclear Medicine
Volume39
Issue number7
StatePublished - Jul 1 1998

Fingerprint

Idoxuridine
Brain Neoplasms
Radiotherapy
Neoplasms
Gliosarcoma
Antineoplastic Agents
Central Nervous System Neoplasms
Radiopharmaceuticals
Poisons
Cytotoxins
Therapeutics
Autoradiography
Meningitis
Ascites
Neuroglia
Radioisotopes
Iodine
Thymidine
Electrons

Keywords

  • 5-iodo-2'-deoxyuridine
  • Auger electrons
  • Brain tumor therapy
  • Iodine-125
  • Locoregional administration

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Kassis, A. I., Wen, P. Y., Van Den Abbeele, A. D., Baranowska-Kortylewicz, J., Makrigiorgos, G. M., Metz, K. R., ... Adelstein, S. J. (1998). 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. Journal of Nuclear Medicine, 39(7), 1148-1154.

5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. / Kassis, Amin I.; Wen, Patrick Y.; Van Den Abbeele, Annick D.; Baranowska-Kortylewicz, Janina; Makrigiorgos, G. Mike; Metz, Kenneth R.; Matalka, Khalid Z.; Cook, Colin U.; Sahu, Shailendra K.; Black, Peter Mc L.; Adelstein, S. James.

In: Journal of Nuclear Medicine, Vol. 39, No. 7, 01.07.1998, p. 1148-1154.

Research output: Contribution to journalArticle

Kassis, AI, Wen, PY, Van Den Abbeele, AD, Baranowska-Kortylewicz, J, Makrigiorgos, GM, Metz, KR, Matalka, KZ, Cook, CU, Sahu, SK, Black, PML & Adelstein, SJ 1998, '5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats', Journal of Nuclear Medicine, vol. 39, no. 7, pp. 1148-1154.
Kassis AI, Wen PY, Van Den Abbeele AD, Baranowska-Kortylewicz J, Makrigiorgos GM, Metz KR et al. 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. Journal of Nuclear Medicine. 1998 Jul 1;39(7):1148-1154.
Kassis, Amin I. ; Wen, Patrick Y. ; Van Den Abbeele, Annick D. ; Baranowska-Kortylewicz, Janina ; Makrigiorgos, G. Mike ; Metz, Kenneth R. ; Matalka, Khalid Z. ; Cook, Colin U. ; Sahu, Shailendra K. ; Black, Peter Mc L. ; Adelstein, S. James. / 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. In: Journal of Nuclear Medicine. 1998 ; Vol. 39, No. 7. pp. 1148-1154.
@article{9244a7747e8e4e4c815e137f1169fa9a,
title = "5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats",
abstract = "Glial neoplasms of the human central nervous system have defied treatment, in part because of the limited selectivity of available cytotoxic agents. The thymidine analog 5-iodo-2'-deoxyuridine radiolabeled with the Auger electron emitter 125I (125IUdR) is highly toxic to dividing cells when it is deoxyribonucleic acid incorporated, but it is relatively innocuous when located outside the nucleus. Previous studies have shown that 125IUdR has significant antineoplastic potential against mammalian cells in vitro and direct administration of 125IUdR is effective therapy for ovarian ascites tumors in mice and neoplastic meningitis in rats. Studies using external gamma imaging and autoradiography have also shown that direct intratumoral administration of 123IUdR/125IUdR into intracerebral 9L gliosarcomas in rats results in selective uptake of the radionuclide into tumor cells. Based on these encouraging results, we have evaluated the therapeutic potential of 125IUdR in rats bearing intracerebral 9L gliosarcomas. Methods: Iodine- 125-IUdR was infused intracerebrally over a 2-day period into rats bearing 1- day-old 9L tumors and over a 6-day period into animals with 9-day-old 9L tumors; equimolar concentrations of 127IUdR were infused into control animals. Tumor growth was monitored by contrast-enhanced 1H MRI and animal survival was followed over time. Results: Intracerebral tumors (3-7 mm) were readily detected by MRI. Tumor-bearing rats treated with 127IUdR succumbed with 17-24 days, whereas tumor-bearing animals treated with 125IUdR survived significantly longer, and 10{\%}-20{\%} of the animals were cured of tumors. Conclusion: These data substantiate the antineoplastic potential of 5-[125I]iodo-2'-deoxyuridine and indicate that it may be a useful agent for the therapy of solid tumors that are accessible to direct radiopharmaceutical administration.",
keywords = "5-iodo-2'-deoxyuridine, Auger electrons, Brain tumor therapy, Iodine-125, Locoregional administration",
author = "Kassis, {Amin I.} and Wen, {Patrick Y.} and {Van Den Abbeele}, {Annick D.} and Janina Baranowska-Kortylewicz and Makrigiorgos, {G. Mike} and Metz, {Kenneth R.} and Matalka, {Khalid Z.} and Cook, {Colin U.} and Sahu, {Shailendra K.} and Black, {Peter Mc L.} and Adelstein, {S. James}",
year = "1998",
month = "7",
day = "1",
language = "English (US)",
volume = "39",
pages = "1148--1154",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

TY - JOUR

T1 - 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats

AU - Kassis, Amin I.

AU - Wen, Patrick Y.

AU - Van Den Abbeele, Annick D.

AU - Baranowska-Kortylewicz, Janina

AU - Makrigiorgos, G. Mike

AU - Metz, Kenneth R.

AU - Matalka, Khalid Z.

AU - Cook, Colin U.

AU - Sahu, Shailendra K.

AU - Black, Peter Mc L.

AU - Adelstein, S. James

PY - 1998/7/1

Y1 - 1998/7/1

N2 - Glial neoplasms of the human central nervous system have defied treatment, in part because of the limited selectivity of available cytotoxic agents. The thymidine analog 5-iodo-2'-deoxyuridine radiolabeled with the Auger electron emitter 125I (125IUdR) is highly toxic to dividing cells when it is deoxyribonucleic acid incorporated, but it is relatively innocuous when located outside the nucleus. Previous studies have shown that 125IUdR has significant antineoplastic potential against mammalian cells in vitro and direct administration of 125IUdR is effective therapy for ovarian ascites tumors in mice and neoplastic meningitis in rats. Studies using external gamma imaging and autoradiography have also shown that direct intratumoral administration of 123IUdR/125IUdR into intracerebral 9L gliosarcomas in rats results in selective uptake of the radionuclide into tumor cells. Based on these encouraging results, we have evaluated the therapeutic potential of 125IUdR in rats bearing intracerebral 9L gliosarcomas. Methods: Iodine- 125-IUdR was infused intracerebrally over a 2-day period into rats bearing 1- day-old 9L tumors and over a 6-day period into animals with 9-day-old 9L tumors; equimolar concentrations of 127IUdR were infused into control animals. Tumor growth was monitored by contrast-enhanced 1H MRI and animal survival was followed over time. Results: Intracerebral tumors (3-7 mm) were readily detected by MRI. Tumor-bearing rats treated with 127IUdR succumbed with 17-24 days, whereas tumor-bearing animals treated with 125IUdR survived significantly longer, and 10%-20% of the animals were cured of tumors. Conclusion: These data substantiate the antineoplastic potential of 5-[125I]iodo-2'-deoxyuridine and indicate that it may be a useful agent for the therapy of solid tumors that are accessible to direct radiopharmaceutical administration.

AB - Glial neoplasms of the human central nervous system have defied treatment, in part because of the limited selectivity of available cytotoxic agents. The thymidine analog 5-iodo-2'-deoxyuridine radiolabeled with the Auger electron emitter 125I (125IUdR) is highly toxic to dividing cells when it is deoxyribonucleic acid incorporated, but it is relatively innocuous when located outside the nucleus. Previous studies have shown that 125IUdR has significant antineoplastic potential against mammalian cells in vitro and direct administration of 125IUdR is effective therapy for ovarian ascites tumors in mice and neoplastic meningitis in rats. Studies using external gamma imaging and autoradiography have also shown that direct intratumoral administration of 123IUdR/125IUdR into intracerebral 9L gliosarcomas in rats results in selective uptake of the radionuclide into tumor cells. Based on these encouraging results, we have evaluated the therapeutic potential of 125IUdR in rats bearing intracerebral 9L gliosarcomas. Methods: Iodine- 125-IUdR was infused intracerebrally over a 2-day period into rats bearing 1- day-old 9L tumors and over a 6-day period into animals with 9-day-old 9L tumors; equimolar concentrations of 127IUdR were infused into control animals. Tumor growth was monitored by contrast-enhanced 1H MRI and animal survival was followed over time. Results: Intracerebral tumors (3-7 mm) were readily detected by MRI. Tumor-bearing rats treated with 127IUdR succumbed with 17-24 days, whereas tumor-bearing animals treated with 125IUdR survived significantly longer, and 10%-20% of the animals were cured of tumors. Conclusion: These data substantiate the antineoplastic potential of 5-[125I]iodo-2'-deoxyuridine and indicate that it may be a useful agent for the therapy of solid tumors that are accessible to direct radiopharmaceutical administration.

KW - 5-iodo-2'-deoxyuridine

KW - Auger electrons

KW - Brain tumor therapy

KW - Iodine-125

KW - Locoregional administration

UR - http://www.scopus.com/inward/record.url?scp=0031595115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031595115&partnerID=8YFLogxK

M3 - Article

C2 - 9669385

AN - SCOPUS:0031595115

VL - 39

SP - 1148

EP - 1154

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 7

ER -